1708 results about "Benzamide" patented technology

The invention discloses novel thiobenzamide compounds. The structure of the thiobenzamide compounds is shown as a general formula I, wherein R1 is selected from Cl or Br; R2 is selected from methyl, isopropyl or allyl; and R3 is selected from H or Cl. The compounds shown in the general formula I have excellent insecticidal activity, and can be used for the control on common pests in agriculture and forestry, especially the control on resistant pests.

Compositions and methods are provided for treating diseases associated with aberrant silencing of gene expression such as cancer by reestablishing the gene expression through inhibition of DNA hypomethylation and histone deacetylase. The method comprises: administering to a patient suffering from the disease a therapeutically effective amount of a DNA methylation inhibitor such as a cysteine analog such as decitabine, in combination with an effective amount of histone deacetylase inhibitor such as hydroxamic acid, cyclic peptide, benzamide, butyrate, and depudecin.

Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

In one aspect, the invention relates to compounds, including phenylethynylbenzamide derivatives, cycloalkylethynylbenzamide derivatives, styrylbenzamide derivatives, 4-(3-phenyl-1,2,4-oxadiazol-5-yl)benzamide derivatives, 4-(pyridinylethynyl)benzamide derivatives, and N¹-phenylterephthalamide derivatives, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The present invention relates to methods for treating cancer comprising utilizing a combination of signal transduction inhibitors. More specifically, the present invention relates to combinations of so called cell cycle inhibitors with mitogen stimulated kinase signal transduction inhibitors, more specifically combinations of CDK inhibitors with mitogen stimulated kinase signal transduction inhibitors, more preferably MEK inhibitors. Other embodiments of the invention relate to additional combinations of the aforesaid combinations with standard anti-cancer agents such as cytotoxic agents, palliatives and antiangiogenics. Most specifically this invention relates to combinations of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one including salt forms, which is a selective cyclin-dependent kinase 4 (CDK4) inhibitor, in combination with one or more MEK inhibitors, most preferably N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide. The aforementioned combinations are useful for treating inflammation and cell proliferative diseases such as cancer and restenosis.

The present invention relates to methods of treating CNS disorders with a compound of formula I

wherein

• • X, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, and R⁸ are as defined in the specification and pharmaceutically acceptable acid addition salts thereof.

There is provided a compound having a capsaicin receptor VR1 inhibitory activity and useful as a therapeutic agent for various pains including inflammatory pain and neurogenic pain, migraine, cluster headache, bladder diseases including overactive bladder, and the like. A benzamide derivative or a salt thereof wherein a benzene ring is attached to a D ring (a monocyclic or bicyclic hydrocarbon ring or a monocyclic or bicyclic heteroaromatic ring) through an amide bond, the benzene ring is directly bonded to an E ring (a monocyclic or bicyclic hydrocarbon ring or a monocyclic or bicyclic heteroaromatic ring), and the benzene ring is further bonded to A (an amino moiety, a monocyclic or bicyclic heterocycle) through L (a lower alkylene).

Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Disclosed are compounds of the formula

or a pharmaceutically acceptable salt or solvate thereof, wherein

• [0001]
  • R¹ is
  [0002]
  • R is —C(O)—N(R²⁷)(R²⁸) or

and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease. Also disclosed are pharmaceutical compositions and methods of treating cognitive or neurodegenerative diseases comprising the compounds of formula I in combination with a β-secretase inhibitor other than those of formula I, an HMG-CoA reductase inhibitor, a gamma-secretase inhibitor, a non-steroidal anti-inflammatory agent, an N-methyl-D-aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody.

The present invention provides a compound represented by the formula (I):

wherein

• ring A is a ring which is optionally further substituted;
• R¹ is a hydrogen atom or a substituent;
• R² is a hydrogen atom or a substituent;
• R³ is a hydrogen atom or a substituent;
• R⁴ is a hydrogen atom or a substituent;
• R⁵ is a hydrogen atom or a substituent;
• R⁶ is a hydrogen atom or a substituent;
• X is ═N— or ═C(Z)- (Z is a hydrogen atom or a substituent);
• when X is ═C(Z)-, Z and R⁶ are optionally bonded to each other to form, together with the carbon atom bonded thereto, an optionally substituted ring,
• provided that when X is ═CH—, then R⁶ is not optionally substituted 2-piperidinyl, excluding N-imidazo[1,2-a]pyridin-2-yl-4-methyl-benzamide, N-imidazo[1,2-a]pyridin-2-yl-benzamide and N-(7-methylimidazo[1,2-a]pyridin-2-yl)-benzamide, or a salt thereof, and a pharmaceutical agent containing same.
• The compound of the present invention has an ASK1 inhibitory action, and is useful as a pharmaceutical agent such as an agent for the prophylaxis or treatment of diabetes, inflammatory diseases and the like, and the like.

The invention relates to a compounded herbicide composition for rice fields, which contains the following two effective components: component (A): pyribenzoxim; component (B): a herbicide which is one of the following compounds: triazines compounds, heterocyclic compounds, phenoxy compounds, amide compounds, diphoenyl ether compounds, sulfonylurea compounds, phenoxyalkanoic acid compounds, botanical compounds, organic phosphorus compounds, urea compounds, dinitroaniline compounds, benzamide compounds and carbamate compounds; and wherein, the weight ratio of the component (A) to the component (B) is 1-50: 1-50.

The invention discloses a benzamide compound with a novel structure and a midbody used for preparing a compound of a formula I which are respectively shown in the formula I and a formula II; the definitions of each substituent group in the formulas can be seen in an instruction; the compound of the formula I has excellent desinsection activity and can be used for controlling pests.

The invention relates to a method of modulating poly(ADP-ribose)polymerase-1 (PARP-1) activity in a mammal comprising administering to a mammal an effective amount of an organic aromatic compound having from 4 to about 35 carbon atoms, wherein said organic aromatic compound is capable of binding the arginine-34 moiety located in Zinc finger-1 of the PARP-1 enzyme and wherein said organic aromatic compound has electron donating capabilities such that it's π-electron system will interact with the positively charged (cationic) guanidinium moiety of the specific arginine-34 residue of the Zinc-1 finger of PARP-1 and does not contain benzamide or lactam substituents. In particular, substituted benzopyrones and substituted indoles and their pharmaceutical compositions containing such compounds that modulate the activity of PARP-1, are described. The invention is also directed to the composition of matter, kits and methods for their therapeutic and/or prophylactic use in treating diseases and disorders described herein, by administering effective amounts of such compounds. Preferably, the compositions and methods provided herein inhibit PARP activity.

Novel pest control agents, particularly insecticides or miticides are provided. Isoxazoline-substituted benzamide compounds of General Formula (1) or a salt thereof:

(where A¹, A² and A³ are independently C or N, G is a benzene ring, etc., Q is a structure of Q-1, Q-2 or Q3:

(where, for example, R¹ in Q-1 is a C₁ to C₄ haloalkyl, etc., and R² is H, etc., R¹ in Q-2 is —OR^1a, etc., R^1a is a C₁ to C₄ alkyl, etc., and R² is H, etc.), W is O or S, X is a halogen atom, a C₁ to C₂ haloalkyl, etc., Y is a halogen atom, a C₁ to C₂ alkyl, etc., R³ is a C₁ to C₂ haloalkyl, etc., m is an integer of 1-3, etc., and n is an integer of 0 or 1, etc.), and pest control agents containing the compounds.

Phenylamino benzoic acid, benzamides, and benzyl alcohol derivatives of the formula

• • where R₁, R₂, R₃, R₄, R₅, and R₆ are hydrogen or substituent groups such as alkyl, and where R₇ is hydrogen or an organic radical, and Z is COOR₇, tetrazolyl, CONR₆R₇, or CH₂OR₇, are potent inhibitors of MEK and, as such, are effective in treating cancer and other proliferative diseases such as inflammation, psoriasis and restenosis, as well as stroke, heart failure, and immunodeficiency disorders.

The present invention relates in general to methods of treating sweating disorders and in particular to topical compositions for the treatment of hyperhidrosis. The methods of the present invention relate to the topical application of a composition comprising a therapeutically effective amount of oxybutynin, tolterodine or a substituted benzamide such as sulpiride.

The novel benzamide derivative represented by formula (1) and the novel anilide derivative represented by formula (13) of this invention has differentiation-inducing effect, and are, therefore, useful a therapeutic or improving agent for malignant tumors, autoimmune diseases, dermatologic diseases and parasitism. In particular, they are highly effective as an anticancer drug, specifically to a hematologic malignancy and a solid carcinoma.

To provide a compound having an excellent inhibitory effect on vanilloid receptor subtype 1 (VR1) activity which is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, neuralgia, etc. and a pharmaceutical composition containing the compound. The object has been attained by a condensed benzamide compound represented by the following formula (the symbols in the formula have the same meanings defined in the specification) or its salt:

The present invention includes peptidomimetic compound compositions and methods of making and using peptidomimetic compounds to modulate the activity of a peptide receptor for the treatment of one or more of hyperglycemia, insulin resistance, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoproteinemia or other symptoms that relate to the function of the targeted receptor. The peptidomimetic includes an oligo-benzamide compound having at least three optionally substituted benzamides.